Curative Biosciences Inc
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. It intends to manufacture and market natural health products and operate in the medical cannabis industry. The company was formerly known as Amaize Beverage Corporation and changed its name to Curative Biosciences, Inc. in August 2017. Curative Biosciences, Inc. was founded in 2009 an… Read more
Curative Biosciences Inc (CBDX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2018: 0.045x
Based on the latest financial reports, Curative Biosciences Inc (CBDX) has a cash flow conversion efficiency ratio of 0.045x as of March 2018.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.51K) by net assets ($-705.67K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Curative Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2017)
This chart illustrates how Curative Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Curative Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curative Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pioneers Properties For Urban Development(PREDCO)
EGX:PRDC
|
N/A |
|
Contact Financial Holding
EGX:CNFN
|
N/A |
|
THE KINGSBURY PLC
CM:SERVN0000
|
N/A |
|
RAIZ4F
SA:RAIZ4F
|
N/A |
|
279060
KO:279060
|
N/A |
|
Volt Group Ltd
AU:VPRDB
|
N/A |
|
Apna Microfinance Bank Ltd
KAR:AMBL
|
N/A |
|
C HUARONG A MGT -H-
STU:CHE
|
N/A |
Annual Cash Flow Conversion Efficiency for Curative Biosciences Inc (2014–2017)
The table below shows the annual cash flow conversion efficiency of Curative Biosciences Inc from 2014 to 2017.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2017-06-30 | $-630.80K | $-12.80K | 0.020x | -56.97% |
| 2016-06-30 | $-615.11K | $-29.00K | 0.047x | -49.80% |
| 2015-06-30 | $-695.80K | $-65.35K | 0.094x | -76.19% |
| 2014-06-30 | $-365.79K | $-144.28K | 0.394x | -- |